Board Change • May 20
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Outside Director Masaru Miura was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Feb 04
Elan Corporation, Annual General Meeting, Mar 25, 2026 Elan Corporation, Annual General Meeting, Mar 25, 2026. Announcement • Feb 10
Elan Corporation, Annual General Meeting, Mar 21, 2025 Elan Corporation, Annual General Meeting, Mar 21, 2025. Announcement • Jan 21
Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others. Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND 180 billion on March 22, 2024. For the period ended December 31, 2023, Tmc Viet Nam Trading reported revenue of VND 150 billion, total assets of VND 210 billion, operating income of VND 6 billion, net income of 2.3 billion and net assets of 57 billion. The transaction has been approved by the board of directors of Elan Corporation. The transaction is expected to close in mid June 2024. As of January 20, 2025, the transaction is expected to close in January 2025.
Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others on January 21, 2025. Announcement • Dec 14
ELAN Corporation Announces CEO Changes, Effective March 21, 2025 ELAN Corporation announced that it has resolved, at a meeting of the Board of Directors held on December 13, 2024, to change the Company's CEO. Hideharu Sakurai is scheduled to retire as CEO and Tomohiro Minezaki, the current COO, will succeed him as CEO. Scheduled date of assuming office is March 21, 2025. Announcement • Dec 10
Elan Corporation to Report Fiscal Year 2024 Results on Feb 10, 2025 Elan Corporation announced that they will report fiscal year 2024 results on Feb 10, 2025 Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: JP¥8.39 (vs JP¥10.50 in 3Q 2023) Third quarter 2024 results: EPS: JP¥8.39 (down from JP¥10.50 in 3Q 2023). Revenue: JP¥12.0b (up 13% from 3Q 2023). Net income: JP¥507.2m (down 20% from 3Q 2023). Profit margin: 4.2% (down from 6.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €5.95, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 14x in the Healthcare industry in Germany. Total loss to shareholders of 36% over the past three years. Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: JP¥9.91 (vs JP¥9.23 in 2Q 2023) Second quarter 2024 results: EPS: JP¥9.91 (up from JP¥9.23 in 2Q 2023). Revenue: JP¥11.4b (up 14% from 2Q 2023). Net income: JP¥599.0m (up 7.3% from 2Q 2023). Profit margin: 5.3% (down from 5.6% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Declared Dividend • Aug 08
Dividend of JP¥14.00 announced Shareholders will receive a dividend of JP¥14.00. Ex-date: 27th December 2024 Payment date: 25th March 2025 Dividend yield will be 290%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (31% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has increased by an average of 32% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 02
Elan Corporation to Report Q2, 2024 Results on Aug 06, 2024 Elan Corporation announced that they will report Q2, 2024 results on Aug 06, 2024 Reported Earnings • May 09
First quarter 2024 earnings released: EPS: JP¥12.01 (vs JP¥11.50 in 1Q 2023) First quarter 2024 results: EPS: JP¥12.01 (up from JP¥11.50 in 1Q 2023). Revenue: JP¥11.5b (up 17% from 1Q 2023). Net income: JP¥726.0m (up 4.5% from 1Q 2023). Profit margin: 6.3% (down from 7.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022) Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • Mar 22
Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion. Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion on March 22, 2024. The transaction is expected to close in mid June 2024. Announcement • Feb 24
Elan Corporation to Report Q1, 2024 Results on May 08, 2024 Elan Corporation announced that they will report Q1, 2024 results on May 08, 2024 Reported Earnings • Feb 16
Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022) Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Feb 15
Elan Corporation, Annual General Meeting, Mar 22, 2024 Elan Corporation, Annual General Meeting, Mar 22, 2024. Upcoming Dividend • Dec 21
Upcoming dividend of JP¥12.00 per share at 1.1% yield Eligible shareholders must have bought the stock before 28 December 2023. Payment date: 27 March 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.2%). Announcement • Dec 05
Elan Corporation to Report Fiscal Year 2023 Results on Feb 14, 2024 Elan Corporation announced that they will report fiscal year 2023 results on Feb 14, 2024 Reported Earnings • Nov 08
Third quarter 2023 earnings released: EPS: JP¥10.50 (vs JP¥9.69 in 3Q 2022) Third quarter 2023 results: EPS: JP¥10.50 (up from JP¥9.69 in 3Q 2022). Revenue: JP¥10.6b (up 16% from 3Q 2022). Net income: JP¥635.0m (up 8.4% from 3Q 2022). Profit margin: 6.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 1.3% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Aug 30
Elan Corporation to Report Q3, 2023 Results on Nov 07, 2023 Elan Corporation announced that they will report Q3, 2023 results on Nov 07, 2023 New Risk • Aug 11
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Aug 09
Elan Corporation Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023 Elan Corporation provided consolidated earnings guidance for the full year ending December 31, 2023. For the year, the company expects net sales of ¥43,700 million, operating profit of ¥3,600 million, profit attributable to owners of parent of ¥2,500 million, and earnings per share of ¥41.35. Reported Earnings • Aug 08
Second quarter 2023 earnings released: EPS: JP¥9.23 (vs JP¥9.11 in 2Q 2022) Second quarter 2023 results: EPS: JP¥9.23 (up from JP¥9.11 in 2Q 2022). Revenue: JP¥9.92b (up 13% from 2Q 2022). Net income: JP¥558.0m (up 1.3% from 2Q 2022). Profit margin: 5.6% (down from 6.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Elan Corporation to Report Q2, 2023 Results on Aug 07, 2023 Elan Corporation announced that they will report Q2, 2023 results on Aug 07, 2023 Reported Earnings • May 12
First quarter 2023 earnings released: EPS: JP¥11.50 (vs JP¥10.35 in 1Q 2022) First quarter 2023 results: EPS: JP¥11.50 (up from JP¥10.35 in 1Q 2022). Revenue: JP¥9.86b (up 12% from 1Q 2022). Net income: JP¥695.0m (up 11% from 1Q 2022). Profit margin: 7.1% (in line with 1Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 30
Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021) Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 12
Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021) Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Dec 28
Elan Corporation to Report Fiscal Year 2022 Results on Feb 09, 2023 Elan Corporation announced that they will report fiscal year 2022 results on Feb 09, 2023 Upcoming Dividend • Dec 22
Upcoming dividend of JP¥10.00 per share Eligible shareholders must have bought the stock before 29 December 2022. Payment date: 24 March 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (4.0%). Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Outside Independent Director Nobuyuki Takagi was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Nov 12
Third quarter 2022 earnings released: EPS: JP¥9.69 (vs JP¥8.70 in 3Q 2021) Third quarter 2022 results: EPS: JP¥9.69 (up from JP¥8.70 in 3Q 2021). Revenue: JP¥9.16b (up 14% from 3Q 2021). Net income: JP¥586.0m (up 11% from 3Q 2021). Profit margin: 6.4% (down from 6.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Aug 31
Elan Corporation to Report Q3, 2022 Results on Nov 10, 2022 Elan Corporation announced that they will report Q3, 2022 results on Nov 10, 2022 Reported Earnings • Aug 12
Second quarter 2022 earnings released: EPS: JP¥9.11 (vs JP¥7.42 in 2Q 2021) Second quarter 2022 results: EPS: JP¥9.11 (up from JP¥7.42 in 2Q 2021). Revenue: JP¥8.81b (up 14% from 2Q 2021). Net income: JP¥551.0m (up 23% from 2Q 2021). Profit margin: 6.3% (up from 5.8% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • May 29
Elan Corporation to Report Q2, 2022 Results on Aug 10, 2022 Elan Corporation announced that they will report Q2, 2022 results on Aug 10, 2022 Reported Earnings • May 15
First quarter 2022 earnings released: EPS: JP¥10.35 (vs JP¥8.37 in 1Q 2021) First quarter 2022 results: EPS: JP¥10.35 (up from JP¥8.37 in 1Q 2021). Revenue: JP¥8.79b (up 17% from 1Q 2021). Net income: JP¥626.0m (up 24% from 1Q 2021). Profit margin: 7.1% (up from 6.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 5.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Board Change • Apr 28
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). VP & Director Yoshiteru Ando was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Apr 08
Elan Corporation to Report Q1, 2022 Results on May 12, 2022 Elan Corporation announced that they will report Q1, 2022 results on May 12, 2022 Announcement • Feb 16
Elan Corporation Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2022 and Year Ending December 31, 2022 Elan Corporation provided consolidated earnings guidance for the six months ending June 30, 2022 and Year Ending December 31, 2022. For the period, the company expects net sales of JPY 17,300 million, operating profit of JPY 1,430 million, profit attributable to owners of parent of JPY 980 million and earnings per share of JPY 16.21.For the year, the company expects net sales of JPY 37,000 million, operating profit of JPY 3,000 million, profit attributable to owners of parent of JPY 2,000 million and earnings per share of JPY 33.08. Announcement • Feb 12
Elan Corporation, Annual General Meeting, Mar 23, 2022 Elan Corporation, Annual General Meeting, Mar 23, 2022. Reported Earnings • Feb 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: JP¥31.48 (up from JP¥23.86 in FY 2020). Revenue: JP¥31.6b (up 21% from FY 2020). Net income: JP¥1.91b (up 32% from FY 2020). Profit margin: 6.0% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jan 17
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be JP¥9.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% per annum over the last 3 years. Earnings per share has grown by 28% per annum over the last 3 years. Upcoming Dividend • Dec 22
Upcoming dividend of JP¥8.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 24 March 2022. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (2.6%). Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS JP¥8.70 (vs JP¥6.24 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥8.06b (up 21% from 3Q 2020). Net income: JP¥526.0m (up 39% from 3Q 2020). Profit margin: 6.5% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Aug 13
Elan Corporation Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021 Elan Corporation provided consolidated earnings guidance for the year ending December 31, 2021. For the year, the company expects net sales of JPY 31,000 million, operating profit of JPY 2,500 million, profit attributable to owners of parent of JPY 1,680 million and earnings per share of JPY 27.72. Reported Earnings • May 15
First quarter 2021 earnings released: EPS JP¥8.37 (vs JP¥5.61 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: JP¥7.52b (up 26% from 1Q 2020). Net income: JP¥507.0m (up 49% from 1Q 2020). Profit margin: 6.7% (up from 5.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 30
Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 40% per year. Is New 90 Day High Low • Feb 20
New 90-day low: €10.60 The company is down 11% from its price of €11.90 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.35 per share. Announcement • Feb 14
Elan Corporation, Annual General Meeting, Mar 23, 2021 Elan Corporation, Annual General Meeting, Mar 23, 2021. Reported Earnings • Feb 14
Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 14
Revenue beats expectations Revenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to grow 14%, compared to a 3.4% growth forecast for the Healthcare industry in Germany. Announcement • Jan 07
Elan Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021 Elan Corporation announced that they will report fiscal year 2020 results on Feb 12, 2021 Upcoming Dividend • Dec 22
Upcoming Dividend of JP¥12.00 Per Share Will be paid on the 26th of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.4% is below the top quartile of German dividend payers (3.5%), and is lower than industry peers (2.1%). Reported Earnings • Nov 19
Third quarter 2020 earnings released: EPS JP¥12.48 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Nov 19
Revenue beats expectations Revenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 14%, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Is New 90 Day High Low • Nov 16
New 90-day high: €22.60 The company is up 21% from its price of €18.70 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.46 per share. Analyst Estimate Surprise Post Earnings • Nov 14
Revenue beats expectations Revenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 13%, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Reported Earnings • Nov 14
Third quarter 2020 earnings released: EPS JP¥12.48 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Sep 28
New 90-day high: €20.60 The company is up 35% from its price of €15.30 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.13 per share. Announcement • Sep 11
Elan Corporation to Report Q3, 2020 Results on Nov 12, 2020 Elan Corporation announced that they will report Q3, 2020 results on Nov 12, 2020 
